Opening Lecture:Prof. Kurt HOSTETTMANN Nature, an almost untapped reservoir of new drugs University of Geneva and Lausanne, Switzerland
17:10 - 17:50
ORAL PRESENTATIONS
17:10 - 17:30
Dr Irmgard IRMINGER-FINGER BARD1 isoforms - oncogenic drivers in cancer: from understanding the biology to tools for cancer detection and treatment Geneva University Hospitals, Switzerland
17:30 - 17:50
Prof. Robin OFFORD Biopharmaceuticals in bulk for the developing world? Mintaka Foundation for Medical Research, Switzerland
17:50 - 18:00
MINI BREAK
18:00 - 18:40
ORAL PRESENTATIONS
18:00 - 18:20
Prof. Dietrich MEBS Peptides protect a frog from the attack by ants University of Frankfurt, Germany
18:20 - 18:40
Prof. Daniel GILLET Broad-spectrum toxin inhibitors protecting mice against ricin CEA, France
18:40 - 19:30
HOT-SPOT PRESENTATIONS
Dr Patrick GARROUSTE Debiopharm presentation Debio RP, Switzerland
Dr Mimoun Z. AYOUB Peptisyntha, technologies that make the difference... Peptisyntha, Belgium
Dr Werner TSCHOLLAR Aveo Partners presentation Aveo Partners AG, Switzerland
Dr Wynne WESTON-DAVIES Bringing natural peptides to the clinic: some practical considerations Varleigh Ltd, United Kingdom
Mr Daniel BIASS Peptidomics of Conus consors Atheris Laboratories, Switzerland
Dr Bart LANDUYT Functional peptidomics for drug development Katholieke Universiteit Leuven, Belgium
Prof. Peter VERHAERT First lustrum of peptidomics laboratory at Delft University of Technology Delft University of Technology, The Netherlands
Dr Michel DE WAARD Smartox presentation Smartox, France
20:00 - ...
SWISS-EVENT DINNER
Monday, April 12 - From Natural Peptides
SESSION II - Bioactivity Guided Drug Discovery
08:15 - 09:00
Invited Lecture:Dr Richard A. HOUGHTEN The direct in vivo screening of mixture-based combinatorial libraries for the identification of novel analgesics Torrey Pines Institute for Molecular Studies, USA
09:00 - 09:40
ORAL PRESENTATIONS
09:00 - 09:20
Prof. Paul M. WATT Phylomer libraries as a structurally rich source of bioactive peptides Phylogica Ltd, Australia
09:20 - 09:40
Prof. Julian WHITE Venom diversity of action and therapeutic opportunities - a clinical toxinologist's perspective Women's & Children's Hospital, Australia
09:40 - 10:10
COFFEE BREAK
SESSION III - In Silico Driven Drug Discovery
10:10 - 10:55
Invited Lecture:Prof. Amos M. BAIROCH The CALIPHO project: bioinformatics and laboratory approaches targeted towards human proteins - some thoughts relevant to peptides Swiss Institute of Bioinformatics, Switzerland
10:55 - 11:30
HOT SPOT PRESENTATIONS
Mrs Silja LAHT Modeling of conopeptide gene superfamilies using Hidden Markov Models in order to facilitate the annotation and prediction of conopeptides Estonian Biocenter, Estonia
Mr Dominique KOUA Bioinformatic platform for hit identification from mass spectra and RNA expression data Atheris Laboratories, Switzerland
Dr Judit TULLA-PUCHE Thiocoraline as a model to improve bioavailability in depsipeptides Barcelona Science Park, Spain
Prof. Songping LIANG Characterization of a group lectin-like peptides from the spider Ornithoctonus huwena Hunan Normal University, China
11:30 - 16:30
ORGANISED RECREATIONAL ACTIVITIES LUNCH BREAK
SESSION IV - Structure-Function & Modelling
17:15 - 18:00
Invited Lecture:Dr Steffen REEDTZ-RUNGE Ligand-bound structures of the GLP-1 receptor extracellular domain Novo Nordisk A/S, Denmark
18:00 - 18:40
ORAL PRESENTATIONS
18:00 - 18:20
Prof. Peter TIMMERMAN Rebuilding protein surfaces using peptide fixation technologies Pepscan Therapeutics BV, Netherlands
18:20 - 18:40
Prof. Julio A. CAMARERO Cyclotides, a novel peptide scaffold for drug discovery University of Southern California, USA
18:40 - 18:50
MINI BREAK
18:50 - 19:10
ORAL PRESENTATION
18:50 - 19:10
Prof. Paul ALEWOOD Solving the α-conotoxin folding problem: efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists University of Queensland, Australia
SESSION V - Lead Validation
19:10 - 19:50
ORAL PRESENTATIONS
19:10 - 19:30
Dr John P. MAYER Discovery of potent, cyclic Calcitonin Gene Related Peptide (CGRP) receptor antagonists Eli Lilly Corporate Center, USA
19:30 - 19:50
Prof. Emanuel ESCHER Synthetic agonists for the CXCR4 chemokine receptor University of Sherbrooke, Canada
19:50 - ...
FREE EVENING
Tuesday, April 13 - Through Development
SESSION VI - Early Development
08:15 - 09:00
Invited Lecture:Dr Derek MACLEAN Intracellular targeting of select protein kinase C isozymes with rationally designed peptides; from the bench to the clinic Kai Pharmaceuticals, USA
09:00 - 10:00
ORAL PRESENTATIONS
09:00 - 09:20
Dr Les MIRANDA Chemistry, biology and structure of hepcidin Amgen Inc, USA
09:20 - 09:40
Dr Reto STÖCKLIN XEP- 018: a new conopeptide lead compound from Conus consors Atheris Laboratories, Switzerland
09:40 - 10:00
Dr Wynne WESTON-DAVIES Coversin, a potent C5 complement inhibitor derived from tick saliva Varleigh Ltd, United Kingdom
10:00 - 10:30
COFFEE BREAK
SESSION VII - Peptide Drug Candidates
10:30 - 11:15
Invited Lecture:Dr Christophe BONNY Clinical development of XG-102, a cell penetrating kinase inhibitor peptide Xigen SA, Switzerland
11:15 - 12:30
Round table:Evaluation, licensing and strategic alliances: how to be successful?
Presentations by
- Kamel BESSEGHIR, CEO, Debiopharm SA, Switzerland
The evaluation of a molecule by a drug development company: some critical aspects
- Werner TSCHOLLAR, Partner, Aveo Partners AG, Switzerland
Evaluation, licensing and strategic alliances: how to be successful? - from a biotech and investors viewpoint
- Peter HOFFMANN, VP, Genzyme Pharmaceuticals, USA
The rise of biotechnology is larger better?
Followed by an open debate.
12:30 - 14:00
LUNCH BREAK
14:00 - 17:00
OPTIONAL ACTIVITIES & NETWORKING SESSIONS
SESSION VIII - Production & Validation
17:00 - 17:45
Invited Lecture:Dr Andrea LEONE-BAY Early development of GLP-1 Technosphere®powder for inhalationMannKind Corporation, USA
17:45 - 19:05
ORAL PRESENTATIONS
17:45 - 18:05
Prof. Kleomenis BARLOS Synthesis of insulin-like peptides by the random folding of the A & B chains University of Patras, Greece
18:05 - 18:25
Dr Matthieu GIRAUD Solid-phase synthesis of the rich Cys containing peptide linaclotide Lonza Ltd, Switzerland
18:25 - 18:45
Dr Hazel MONCRIEFF Challenges in the manufacture of long peptides for clinical development Almac Sciences, United Kingdom
18:45 - 19:05
Dr Gery VAN VYNCHT From dedicated method development to early stability studies of low dosage forms of lyophilised peptide-based drug products Quality Assistance SA, Belgium
20:00 - ...
GALA DINNER
Wednesday, April 14 - To Clinics
SESSION IX - Delivery & Membrane Interaction
08:15 - 09:00
Invited Lecture:Dr Gregor CEVC Non-invasive and targeted transcutaneous delivery of drugs, including peptides Pamet AG, Germany
09:00 - 09:40
ORAL PRESENTATIONS
09:00 - 09:20
Dr Rainer HENNING Fibrin derived peptides as natural endothelial protectants: mechanism of action and therapeutic use Fibrex Medical Inc, Austria
09:20 - 09:40
Prof. Jon NISSEN-MEYER Bacterial antimicrobial peptides act as ligands that bind to (transport) proteins in bacteria membranes and thereby induce membrane leakage and cell death University of Oslo, Norway
09:40 - 10:00
Prof. Manfred MUTTER Switch-peptides in Alzheimer research Debio RP, Switzerland
10:00 - 10:15
HOT SPOT PRESENTATIONS
Dr Michel GEFFARD Alternative antimicrobial polypeptide in the resistance against microorganisms IDRPHT, France
Prof. Dirk A. TOURWÉ Optimisation of the polarity of radiolabeled bombesin(7-14) provides excellent tracers for tumor detection using SPECT Vrije Universiteit Brussel, Belgium
10:15 - 10:45
COFFEE BREAK
SESSION X - Drug Development
10:45 - 11:30
Invited Lecture:DrAbdellah SENTISSI TM601's: present and future applications in the clinic TransMolecular Inc., USA
11:30 - 12:10
ORAL PRESENTATIONS
11:30 - 11:50
Dr Daniel OBRECHT From the natural peptide protegrin to POL7080: a novel class of antibiotics targeting proteins involved in the outer membrane biogenesis in Pseudomonas aeruginosa Polyphor Ltd, Switzerland
11:50 - 12:10
Dr George MILJANICH The anti-depressant and anxiolytic properties of the tetrapeptide, GLYX-13: a glycine-site functional partial agonist of NMDA receptors Airmid Inc, USA
12:10 - 12:30
Prof. Juergen K. ENGEL AEZS-108: from LHRH agonists to a new drug targeting concept in oncology AEterna Zentaris, Germany
12:30 - 13:15
Closing Lecture:Prof. Janice M. REICHERT Peptides to drugs pipeline Tufts University and Peptide Therapeutics Foundation, USA
13:15 - 13:25
Closing Notes
13:30- ...
FAREWELL COCKTAIL / LUNCHEON
Discovery of Potent, Cyclic Calcitonin Gene Related Peptide (CGRP) Receptor Antagonists
